![How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download](https://images.slideplayer.com/23/6590870/slides/slide_3.jpg)
How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download
![Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial - The Lancet Infectious Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial - The Lancet Infectious](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/6e926951-4fe9-4bc3-867e-282c85d76fd7/gr1.jpg)
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial - The Lancet Infectious
![Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram](https://www.researchgate.net/profile/Herbert-Baraf/publication/233396586/figure/fig4/AS:289187577253918@1445959099647/Figure1-Study-design-schematic-for-the-open-label-extension-study-AE-adverse-event-IR.png)
Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram
PLOS ONE: A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
![Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2080812205/2072208225/gr1.jpg)
Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology
![Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals](https://www.concertpharma.com/wp-content/uploads/2019/06/clinicaltrials-2-e1566478031946.jpg)
Understanding Clinical Trial Terminology: What is an Open Label Clinical Trial? - Concert Pharmaceuticals
![A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13063-019-3766-9/MediaObjects/13063_2019_3766_Fig1_HTML.png)
A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults
![Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial - The Lancet Neurology Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/e53ef392-4fec-49e2-b653-2896383e183d/gr1.gif)
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial - The Lancet Neurology
![Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). | Semantic Scholar Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1cddd261551d50318e376dfb82aed83eb00d7466/4-Table1-1.png)
Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). | Semantic Scholar
![Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo - eClinicalMedicine Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/618f5366-326d-4aac-9d85-05c9687bd2d1/gr1_lrg.jpg)
Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo - eClinicalMedicine
![Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4ba8a139-a98a-4306-9ae7-443a9ad74d47/gr1_lrg.jpg)
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology
![Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol](https://bmjopen.bmj.com/content/bmjopen/3/7/e002902/F1.large.jpg)
Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol
![An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-019-1857-3/MediaObjects/13075_2019_1857_Fig1_HTML.png)
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
![PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/814ad6ccbfa9defca4d2b00c4672f9070cf6b8da/16-Figure1-1.png)
PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar
![A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41436-020-01006-8/MediaObjects/41436_2020_1006_Fig1_HTML.png)
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine
![Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f5b9964c-4331-4321-a712-8d6a65155a91/gr1_lrg.jpg)